An antagonist of Bcl-2 family proteins, Sabutoclax, downregulates survivin through IL-6/Stat3 signaling pathway, to improve chemosensitivity in breast cancer CSCs [229]. This evidence concerns the gene BIRC5 and breast carcinoma.